Science and Technology
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
COMP360 Psilocybin for Treatment-Resistant Depression
Markets
Before 2028
91%
Before October 2027
84%
Before July 2027
75%
Before Mar 1, 2027
49%
Before Jan 1, 2027
19%
Rules
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
Outcome verified from Food and Drug Administration.
Additional prohibitions
- Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
- Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.
Legal
By trading on this market, you agree to the Trading prohibitions, Member agreement, and DFlow terms of service.